Routine Fixation of Humeral Shaft Fractures is Cost-Effective: Cost-Utility Analysis of 215 Patients at Five Years Following Injury William M. Oliver, MBBS, MRCSED; Samuel Molyneux, FRCS (Ortho), MSc; Timothy O. White, MD, FRCS; Nicholas D. Clement, FRCS (Ortho); Andrew David Duckworth, PhD, MSc Royal Infirmary of Edinburgh, Edinburgh, UNITED KINGDOM

Purpose: The primary aim of this study was to estimate the cost-effectiveness of routine fixation for all patients with humeral shaft fractures. The secondary aim was to estimate the health economic implications of using a Radiographic Union Score for HUmeral fractures (RUSHU) <8 to facilitate selective fixation for patients at risk of nonunion.

Methods: From 2008 to 2017, 215 adult patients (mean age 57 years [range, 17-18], 61% female) with a nonoperatively managed humeral diaphyseal fracture were retrospectively identified. Union was achieved in 77% (n = 165/215) after initial management, with 23% (n = 50/215) uniting after surgery for nonunion. Costs were measured in Pounds Sterling (GBP) and based on the English National Health Service tariff or departmental procurement costs. The EuroQol 5-Dimension (EQ-5D) 3-Level Health Index was obtained via postal survey. Multiple regression was used to determine the independent influence of patient, injury, and management factors upon the EQ-5D. An incremental cost-effectiveness ratio (ICER) of <£20,000 (\$25,000) per quality-adjusted life year (QALY) gained was considered cost-effective.

Results: At a mean of 5.4 years (range, 1.2-11.0), the mean EQ-5D was 0.736 (95% confidence interval [CI] 0.697 to 0.775). Adjusted analysis demonstrated the EQ-5D was inferior among patients who united after nonunion surgery ($\beta = 0.103$, P = 0.032). Offering routine fixation to all patients in order to reduce the rate of nonunion would be associated with increased overall treatment costs of £1,542 / patient (\$2,000), but would confer a potential EQ-5D benefit of 0.120 / patient over the 5-year period of study follow-up. The ICER of routine humeral shaft fracture fixation was £12,850 (\$16,000) per QALY gained. Selective fixation, based on a RUSHU <8 at 6 weeks post-injury, would be associated with reduced treatment costs of £415 / patient (\$500) and conferred a potential EQ-5D benefit of 0.335 per at-risk patient over the 5-year period of study follow-up.

Conclusion: Routine fixation for patients with humeral shaft fractures, in order to reduce the rate of nonunion following nonoperative management, appears to be a cost-effective intervention at 5 years post-injury. Selective fixation of patients at risk of nonunion based upon their RUSHU may confer even greater cost-effectiveness, given the potential cost savings and improvement in health-related quality of life.

The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or medical device they wish to use in clinical practice.